Notice of AGM

RNS Number : 2285K
Induction Healthcare Group PLC
20 December 2022
 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Notice of AGM

 

Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems worldwide, announces that the Notice of Annual General Meeting ("AGM") and associated Form of Proxy are now available on the Company's website and have been posted to those shareholders who have opted out ofelectronic communications (together with a paper copy of the Annual Report).

 

The documents are available here: https://inductionhealthcare.com/investors/financial-reports-and-publications/

 

The Company's AGM will be held at 50 Liverpool Street, London EC2M 7PY at 9.30am (GMT) on Wednesday 11 January 2023.

 

Shareholders are strongly encouraged to complete and return the Form of Proxy in accordance with the instructions set out, to the Company's registrars, Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA, as soon as possible but in any event so as to arrive no later than 9.30am GMT on Monday 9 January 2023.

 

Alternatively, eligible shareholders who hold their shares in the Company in uncertificated form in CREST may use the CREST Proxy Voting Service, details in respect of which are contained in the notes to the notice of the AGM. Electronic Proxy Appointment is also available for this meeting. To use this facility shareholders must visit www.sharevote.co.uk where details of the procedure are shown. Details on how to lodge votes electronically are contained within the notes to the notice of the AGM.

 

The results of voting on the resolutions will be announced via a regulatory information service and posted on the Company's website as soon as practicable after the AGM.

 

In order to give shareholders a chance to engage in a meaningful dialogue with the Company's management, shareholders are encouraged to email Induction's Company Secretary at legal@inductionhealthcare.com with any questions on the business of the AGM or the Report and Accounts in advance of the meeting stating your name (as printed on your form of proxy). The questions will be collated and a representative sample will be selected to be answered on the Company's website at https://inductionhealthcare.com/ as soon as practicable after the conclusion of the AGM. The Company will also endeavour to provide answers directly to shareholders who submitted the questions as soon as reasonably practical.

 

 

ENQUIRIES

 

Induction

James Balmain, Chief Executive Officer

Christopher Samler, Non-Executive Chair

Via Walbrook PR Ltd: induction@walbrookpr.com



Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

Philip Davies / Kailey Aliyar




Walbrook PR Ltd 

induction@walbrookpr.com

Alice Woodings / Paul McManus

Mob: +44 (0)7407 804 654 / +44(0)7980 541 893

 

About Induction - www.inductionhealthcare.com

Induction (AIM: INHC) Induction delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFFFFWUEESEEE
UK 100